⌕
Regeneron Pharmaceuticals · REGN · Nasdaq
Tenet 64 · Solid
Compare
$952.40−0.32%At closeTenet 64 · Solid
$952.40−3.07 (−0.32%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
$951.01−1.39 (−0.15%)
After hours: Nov 16, 2026, 4:43 PM ET

Regeneron Pharmaceuticals (REGN) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● FXEmpireNov 16, 2026 · 16:51 ET
REGN Price Forecast: Rally Faces Resistance After 37% Advance

Regeneron shares face growing resistance after a 37% advance, with potential correction targets emerging while the intermediate- and long-term bullish trends remain intact.…

● The Motley FoolNov 14, 2026 · 07:05 ETEARNINGS EXPECTED BY FEB 1
Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?

Regeneron sells 16 products, and they have helped revenue climb in recent years. The company's leading products delivered record revenue in the third quarter.…

● Defense WorldNov 13, 2026 · 03:51 ETEARNINGS EXPECTED BY FEB 1
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by AlphaCore Capital LLC

AlphaCore Capital LLC lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 133.5% in a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange Commissio…

● GlobeNewsWireNov 12, 2026 · 17:00 ET
POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms

Data presented today for the first time at the American Autonomic Society (AAS) annual meeting POTS (postural orthostatic tachycardia syndrome) is a debilitating condition characterized by a marked increase in heart rate…

● Zacks Investment ResearchNov 12, 2026 · 13:25 ET
REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock?

Regeneron's strong Eylea HD and Dupixent sales, expanding oncology portfolio and promising pipeline fuel growth prospects as Eylea faces intensifying competition.…

● Zacks Investment ResearchNov 11, 2026 · 17:21 ET
Why Regeneron (REGN) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.…

● Seeking AlphaNov 10, 2026 · 16:01 ET
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH Transcript…

● 24/7 Wall StreetNov 10, 2026 · 13:17 ET
Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later?

One biotech pays retirees a bigger check today, while the other carries no net debt and is growing far faster. We put Amgen and Regeneron side by side on income, valuation, and growth to see which one earns a spot in a r…

● MarketBeatNov 10, 2026 · 12:17 ET
Regeneron Pharmaceuticals Advances Liver Drug After Early Trial Cuts Liver Fat by Up to 80%

Regeneron Pharmaceuticals NASDAQ: REGN is advancing its experimental CIDEB therapy into later-stage studies for a form of liver disease after an early trial showed a single dose substantially reduced liver fat, executive…

● Defense WorldNov 7, 2026 · 07:05 ET
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock: Insider Huda Zoghbi Sells 7,439 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) Director Huda Zoghbi sold 7,439 shares of the firm's stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $970.46, fo…

● Defense WorldNov 7, 2026 · 05:16 ET
Regeneron Pharmaceuticals (NASDAQ:REGN) EVP Sells $4,311,878.34 in Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) EVP Joseph Larosa sold 4,466 shares of the firm's stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $965.49, for…

● Defense WorldNov 5, 2026 · 07:19 ETEARNINGS EXPECTED BY FEB 1
Regeneron Pharmaceuticals, Inc. $REGN Stock Purchased by Compass Financial Management LLC

Compass Financial Management LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 4,526.2% in a recent quarter, according to its most recent Form 13F filing with the Securities and Exchange C…

● Defense WorldNov 5, 2026 · 06:05 ETEARNINGS EXPECTED BY FEB 1
Regeneron Pharmaceuticals, Inc. $REGN Stock: AIA Group Ltd Decreases Holdings

AIA Group Ltd cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 37.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owne…

● Defense WorldNov 5, 2026 · 04:17 ETEARNINGS EXPECTED BY FEB 1
Regeneron Pharmaceuticals, Inc. $REGN Stock: Bank Julius Baer & Co. Ltd Zurich Raises Stake

Bank Julius Baer and Co. Ltd Zurich boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 165.2% in the third quarter, according to the company in its most recent Form 13F filing with the Secur…

● Zacks Investment ResearchNov 4, 2026 · 13:20 ETEARNINGS EXPECTED BY FEB 1
Why Regeneron (REGN) Might be Well Poised for a Surge

Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.…

● Zacks Investment ResearchNov 4, 2026 · 12:41 ET
REGN vs. ILMN: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity…

● BenzingaNov 3, 2026 · 07:06 ET
UnitedHealth, Cleveland-Cliffs, Regeneron Pharmaceuticals And More: CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Cerity Partners, picked Cleveland-Cliffs Inc. (NYSE:CLF).…

● Defense WorldNov 3, 2026 · 04:38 ETEARNINGS EXPECTED BY FEB 1
3,572 Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by International Assets Investment Management LLC

International Assets Investment Management LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 356.8% during the third quarter, according to its most recent disclosure with the Securities…

● GlobeNewsWireNov 2, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Jefferies Global Healthcare Conference in London at 2:00 p.m.…

● BenzingaNov 2, 2026 · 09:01 ETEARNINGS EXPECTED BY FEB 1
These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported better-than-expected third-quarter 2026 results. Regeneron reported adjusted earnings of $20.07 per share, up 70% year over year and above the analyst conse…

● GlobeNewsWireOct 30, 2026 · 06:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 1
Regeneron Reports Third Quarter 2026 Financial and Operating Results

TARRYTOWN, N.Y., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the third quarter of 2026 and provided a business update.…

● GlobeNewsWireOct 26, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense , adding value of approximately $270 million…

● GlobeNewsWireOct 12, 2026 · 12:06 ETEARNINGS EXPECTED BY FEB 1
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension

Pasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with FOP Late-breaking da…

● GlobeNewsWireOct 6, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo ® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation…

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 1. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Quiet tape today.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.